Sarah Hein

Science nerd and biotech entrepreneur. Half this feed will be animals.

[Sarah Hein @SarahHein0]

Thank you to @BiotechTVHQ for spending some time in Houston with me and @jbbock at CTMC to talk about how we're bringing our CAR-T with best in class potential to more patients with T cell lymphoma

Series A is open for those interested in joining a clinical-stage story

[BiotechTV @BiotechTV]

Bright Minds: An entrepreneur describes launching a cell therapy startup in Houston.

March Biosciences’ Co-Founder & CEO Sarah Hein on the infrastructure in Houston, and the science behind her company’s CD5 CAR-T.

Full video: https://t.co/U5DelLJ8pI

[BiotechTV @BiotechTV]

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma. Co-Founder and CEO @SarahHein0 walks us through it.

Full video: https://t.co/Je7pUlZPUb

[Sarah Hein @SarahHein0]

@eperlste Way to recognize the biggest name to boost your profile instead of the leads of this spectacular project, Drs. Ahrens-Nicklas, Musunuru, and Grandinette.

[Sarah Hein @SarahHein0]

@eperlste Well if you publish it on your own substack it must be true. After all, the peer review process is a racket with all those highly trained scientists donating their knowledge for free, amiright?

[Sarah Hein @SarahHein0]

@RobertLKruse @Mykalt45 We're just doing our job - getting innovative products to patients!

[Heczey Lab @HeczeyLab]

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
https://t.co/ybNobLrQvy

[Sarah Hein @SarahHein0]

Thank you to @bradloncar of @BiotechTVHQ for coming back to Houston to hear the updates at March Bio 🤠

[BiotechTV @BiotechTV]

𝐓𝐞𝐱𝐚𝐬 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐅𝐨𝐫𝐮𝐦: March Biosciences' CEO @SarahHein0 talks about closing a $28.4M series A round last month to advance its CD5 targeting CAR-T.

Full video: https://t.co/L46ggvouW5

[Sarah Hein @SarahHein0]

🤞🏻🇺🇸

[Michael Torres @Mykalt45]

When a $350B+ pharma invites you to their event at World ADC, you know you’re doing something right!

With our financing done (PR soon), we’re excited to keep building and derisking our platform.

Go, @CrossBridgeBio! Look forward to connecting with future collaborators!

[Sarah Hein @SarahHein0]

I am voting for Kamala, and I hope you will vote with me

Vote for somebody who loves the country and is looking to build a brighter future for all of us. Who respects women, immigrants, and all the people of this country.

Vote against Trump. Fascist. Senile. Weak. Let's move on

[Headquarters @HQNewsNow]

.@Eminem: I don't think anyone wants an America where people are worried about retribution of what people will do if you make your opinion known. I think Vice President Harris supports a future for this country where these freedoms and many others will be protected and upheld

[Sarah Hein @SarahHein0]

Despite the rebound of the mega-financings, first financings are still way down overall. Interesting review by @LifeSciVC

https://t.co/sOyK5atXvV

[Sarah Hein @SarahHein0]

Well this is cool
https://t.co/JzdrgfRIi4

[Sarah Hein @SarahHein0]

Will be interesting to see the results. The side effects of high dose lymphodepletion are under discussed, and despite this nobody has (yet) cracked the code on durability.

Versus just making autologous cheaper and faster, which so far is working industry wide

[Jacob Plieth @JacobPlieth]

$PSTX will have an update on P-BCMA-ALLO1 (remember the #ASH23 dredged dataset) in post-BCMA patients at #AACR24 https://t.co/VF5W9Gyewx

[Sarah Hein @SarahHein0]

Patients like Melissa are why we do what we do.

It's a privilege to get to participate in moving this forward to Phase 2 studies to reach even more patients with T-cell lymphoma

Thank you to the @HoustonChron and @evanmac3 for highlighting this work

https://t.co/Rox9BmJ0kk

[Sarah Hein @SarahHein0]

👏🏻👏🏻👏🏻

[Sarah Hein @SarahHein0]

@RySciComms Wow thank you for getting such a great picture! Was a pleasure to join and get to share our story

[Ry Leahy @RySciComms]

Sarah Hein, March Bio discusses their CAR T pipeline on the Innovation stage at #ATW24

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Secondary myeloid malignancies are more common in the population eligible for CAR T and those eligible for HCT. Discussed here: https://t.co/E4FwVb4LcY
Some refs: Brown, J. R. et al. J. Clin. Oncol. 23, 2208–2214 (2005), Schaapveld, M. et al. N. Engl. J. Med. 373, 2499–2511 (2015), Spencer Chapman, M. et al. Nat. Med. 29, 3175–3183 (2023).
Also see #myeloma expert @RahulBanerjeeMD https://t.co/ZyC4g50gzy

[Sarah Hein @SarahHein0]

How did nobody tell me Disney had added back the full length version of Muppet Christmas Carol, but it's buried under "extras"?

Best. Christmas. Present.